Articles tagged with Drug Studies
A new study from UCLA Health Jonsson Comprehensive Cancer Center introduces a combined genetic and functional profiling approach to predict how glioblastoma will respond to therapy. The approach helps identify new ways to target and treat the tumors more effectively, including using an experimental drug called ABBV-155.
A phase 2b clinical trial found that sodium oxybate, an oral medication mimicking alcohol's effects, significantly improves symptoms of patients with laryngeal dystonia who respond to alcohol. The treatment provided up to 5 hours of voice relief, with no serious adverse events.
A clinical trial testing muvalaplin, a novel oral medication, safely and effectively lowered high levels of Lp(a), a type of inherited cholesterol. The study found that muvalaplin disrupted the formation of the Lp(a) particle, acting as an effective approach to lowering Lp(a) levels.
A new study from Karolinska Institutet found that long-term use of common cardiovascular drugs is associated with a lower risk of dementia. The study, which analyzed data from over 880,000 people, shows that these medications can reduce dementia risk by 4-25%.
A promising daily tablet, infigratinib, has been shown to increase height and improve proportional limb growth in children with achondroplasia. The medication is safe and effective in treating children aged 3-11 years, offering an alternative to existing treatments.
Researchers found that sacubitril-valsartan, a commonly prescribed heart failure medication, can help prevent heart damage related to chemotherapy treatment among high-risk cancer patients. The study highlights the importance of identifying patients at high risk for heart damage and suggests strategies for early intervention.
A nasal spray form of bumetanide has been found to reduce tissue swelling in heart failure as effectively as standard oral and intravenous formulations. This new treatment option could provide a valuable tool for treating heart failure, promoting care at home and reducing hospital admissions.
A recent study found that electronic letter reminders highlighting the cardiovascular benefits of influenza vaccines increased vaccination rates among over 2 million adults in Denmark. The strategy showed a greater impact on those who have had a heart attack, improving flu shot rates by potentially being cardioprotective. The research ...
Research found that spironolactone reduced the likelihood of heart failure after a heart attack, but did not significantly reduce deaths or other severe heart-related events. The study included over 7,000 adults in 14 countries who had experienced a severe heart attack.
A study found that 64% of clinical trials for the top 30 highest-revenue medicines had their data accessible to researchers, a significant improvement over prior assessments. Companies using independent platforms achieved higher eligibility rates than those relying on internal processes.
A randomized trial found reconditioned pacemakers comparable to new devices in terms of safety and effectiveness up to 90 days after implantation. However, longer-term follow-up is necessary to confirm the safety and efficacy of reconditioned devices.
A clinical trial found that combining two commonly recommended medications into a single pill lowered blood pressure and was safe among Indian adults. The study's results have significant meaning for South Asian adults, including those living in the US.
A large-scale clinical trial found that intravenous infusion of exenatide during heart surgeries involving bypass did not significantly reduce the risk of death, stroke, or organ failure. The study included approximately 1,400 adults and a randomized, double-blind, placebo-controlled design.
The international SUMMIT trial found tirzepatide lowered the risk of worsening heart failure events and cardiovascular death in obese adults with preserved ejection fraction. Participants experienced improved health status, physical function, and exercise tolerance compared to placebo.
A recent study published at the American Heart Association's Scientific Sessions 2024 found that blood thinners did not reduce cognitive decline in adults younger than age 65 who have atrial fibrillation (AFib) but no other risk factors for stroke. The trial included over 1,200 participants and followed them for an average of 3.7 years...
A new combination of immunotherapy and epigenetic drug may transform resistant pancreatic tumors into susceptible ones, according to a study by Johns Hopkins Medicine researchers. The treatment showed promise in a subset of patients, with tumor shrinkage and durable responses observed over several months.
New treatment combinations and predictive biomarkers hold promise for improving bladder cancer outcomes. The NIAGARA trial showed that combining immune checkpoint inhibitors with chemotherapy can significantly increase two-year survival rates and reduce cancer recurrences.
A clinical study found that an FasL inhibitor, asunercept, led to a faster recovery of COVID-19 patients in eight days compared to 13 days in the control group. The treatment also reduced mortality by about 20%. The study suggests a new therapeutic concept for severe COVID-19.
Developed by University of Copenhagen researchers, a new nanofiber patch reduces psoriasis treatment frequency to once a day, improving comfort for patients. The patch releases two active ingredients at different rates, addressing the need for multiple products in psoriasis treatment.
Research by the University of Sydney has identified CBN as a constituent that improves sleep in rats. The study showed that CBN increased both NREM and REM sleep, leading to increased total sleep time.
A large international study found that very early medication abortion is equally effective and safe as waiting for intrauterine pregnancy confirmation. The study included over 1,500 women who received two drugs – mifepristone and misoprostol – in either a delayed or early abortion group.
A study found that using an orbital atherectomy device to remove calcium from blocked coronary arteries before stenting procedures did not improve patient outcomes. The device was used on patients with moderately severe calcification, rather than extreme cases, and did not show significant benefits.
Researchers have developed a technology called FarrSight-Twin that creates digital twins of real cancer patients to predict treatment response. The approach was tested on published clinical trials and showed accurate predictions in all simulated studies, with 75% response rate among patients receiving the predicted best treatment.
TYRA-300 shows promise in treating metastatic bladder cancer patients with FGFR3 gene mutations, achieving a 50% overall response rate and 100% disease control rate. The treatment also displays improved tolerability with lower side effects compared to existing pan-FGFR inhibitors.
Researchers developed a nanomedicine that attacks bacteria at the molecular level, reducing antibiotic resistance and side effects. The technology releases medication only when required, ensuring patients take exact amounts to fight infections.
A clinical trial suggests that tucatinib and trastuzumab may benefit patients with rare bile duct cancer who also have HER2-mutated breast cancer. The treatment combination showed a 46.7% objective response rate in patients with bile duct cancer, compared to 22.2% in the broader patient group.
Researchers at USC Dornsife discover that mifepristone increases mitophagy to the same extent as rapamycin, potentially extending lifespan. The study found that combining the two drugs does not offer additional benefits and slightly reduces lifespan, suggesting they act through the same biological pathway.
The use of GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors in people with type 1 diabetes has significantly increased between 2010 and 2023. This trend is driven by their benefits in weight management and cardiorenal protection, but caution is advised due to concerns about euglycemic diabetic ketoacidosis.
A new study found that long-term, low-dose valacyclovir treatment significantly reduces the risk of vision-damaging bouts of inflammation and infection in patients with shingles. Participants treated for a year saw a 26% reduction in eye disease flare-ups at 18 months.
A new study has found that men and women utilize different biological systems to relieve pain. Women rely on non-opioid based pathways, which may explain why they respond poorly to opioid therapies and are more likely to become addicted. The research suggests tailoring pain treatment to an individual's sex may improve patient outcomes.
Researchers at Johns Hopkins Medicine developed a potential novel treatment for breast cancer bone metastasis using RK-33, which targets and inhibits the protein DDX3. The drug successfully eliminated breast cancer bone metastases in lab models by controlling cancer cell growth and proliferation.
A new study found that 5-fluorouracil kills cells by interfering with RNA synthesis, not DNA damage. The findings suggest that combining 5-FU with drugs affecting RNA synthesis could make it more effective in patients with gastrointestinal cancers.
Researchers have developed a peptide inhibitor called RI-AG03 that effectively prevents Tau protein aggregation in lab and fruit fly studies. The breakthrough targets both major aggregation-promoting 'hotspots' of the Tau protein, potentially paving the way for more effective treatments for neurodegenerative diseases.
Researchers have developed a promising new drug, RI-AG03, that successfully targets and blocks both major aggregation-promoting 'hotspots' of the Tau protein. The peptide-based approach shows significant potential in preventing the build-up of Tau proteins and neurodegeneration, addressing a critical gap in current treatments.
A new clinical trial reveals that synthetic cannabis, specifically dronabinol, can effectively reduce agitation in patients with Alzheimer's disease by an average of 30%. The treatment showed similar calming effects to current medications without adverse results such as delirium or seizures.
A new trial suggests that adding immunotherapy to chemoradiation can extend survival in patients with limited-stage small cell lung cancer. However, the findings also indicate that delivering the treatments at different times yields varying results, with concurrent treatment not offering improved survival benefits.
Researchers found lamotrigine to reduce stiffness in non-dystrophic myotonias by around the same amount as mexiletine, offering a new treatment option. The trial results have direct implications for patient care and provide more 'real-world' options for patients with this life-changing muscle disorder.
A new study reveals how psilocybin alters brain connectivity to alleviate symptoms of body dysmorphic disorder, potentially aiding treatment. Psilocybin strengthens neural connections between executive functions and emotionally salient stimuli, leading to improved BDD symptoms.
Researchers at ETH Zurich have found an antidepressant, vortioxetine, effective against glioblastomas, a particularly aggressive brain tumor with no cure. The drug's ability to cross the blood-brain barrier and trigger a signalling cascade makes it promising for treating this deadly tumour.
Researchers confirm that fibrosis in HER2-negative breast tumors is associated with an adverse prognosis and better treatment outcomes with nintedanib. A new test, MeCo Score, analyzes gene activity related to fibrosis and indicates the effectiveness of supplementing chemotherapy with antifibrotic therapy.
A phase 1b/2 clinical trial found a combination of immunotherapy and FGFR inhibitor to be safe and tolerable in patients with locally advanced or metastatic bladder cancer. The treatment showed increased response rates, including 54% for patients with high FGFR mRNA expression.
Researchers at Tel Aviv University discovered that aneuploid cells, which have an abnormal number of chromosomes, are more susceptible to certain types of anticancer drugs. The studies found that disrupting the MAPK pathway increases the sensitivity of these cancer cells to chemotherapy.
Researchers found a significant reduction in nosebleed severity, fewer transfusions, and improved quality of life in patients with hereditary hemorrhagic telangiectasia treated with pomalidomide. The trial's results offer hope for people with this rare bleeding disorder.
A recent clinical trial found that an IV iron treatment called ferric carboxymaltose works faster and better than oral iron tablets in treating anaemia during pregnancy. The study showed improved haemoglobin levels and iron correction with the IV treatment, with comparable side effects.
Researchers found pomalidomide to be safe and effective in reducing nosebleed severity, improving quality of life, and decreasing the need for blood transfusions in adults with hereditary hemorrhagic telangiectasia. The trial stopped early due to successful findings, offering a promising treatment option for this rare bleeding disorder.
A clinical trial found that an oral cancer drug reduced nosebleed severity and improved quality of life in patients with hereditary hemorrhagic telangiectasia (HHT). The PATH-HHT study showed significant improvements in disease manifestations, including severe nosebleeds and chronic gastrointestinal bleeding.
A systematic review of studies on antiseizure drugs in men with epilepsy suggests that there is no clear evidence of a detrimental impact on offspring outcomes. While some isolated harmful side effects were found, they were not replicated in other investigations. The review casts doubt on the stance taken by the UK drugs regulator and ...
Researchers discovered a novel treatment that extends ovarian function in older mice by improving maintenance of the ovaries and preventing key age-related changes. The treatment also fixes hormone production and overall health, alleviating symptoms such as bone loss, cardiovascular disease, and cognitive decline.
The CheckMate 067 trial showed that combining nivolumab and ipilimumab improved outcomes for metastatic melanoma patients, with a median survival time over six years. Long-term follow-up found no new safety signals for the treatment, and metastatic melanoma survivors become increasingly likely to die of other causes as they age.
The RESILIENCE clinical trial explores the effectiveness of remote ischemic conditioning to prevent cardiotoxicity in lymphoma patients undergoing anthracycline-based chemotherapy. The trial aims to reduce heart failure prevalence and improve quality of life for cancer survivors.
A drug that delivers chemotherapy directly to tumors has shown substantial and durable activity in treating brain metastases of HER2-positive breast cancer. The treatment, trastuzumab deruxtecan, has improved progression-free survival and objective response rates in patients with advanced disease.
A post-hoc analysis of the SURMOUNT trials found that tirzepatide consistently reduced body weight in both males and females, but women experienced greater weight loss with up to 24.6% reduction compared to 18.1% for men. The safety profile was broadly similar by sex, but females were more likely to experience nausea and vomiting.
A study published in the journal Brain shows that increases in protein levels with new Alzheimer's drugs can explain the slowing of cognitive impairment at least as well as the reduction in amyloid plaques. The researchers found that higher levels of a critical brain protein correlate equally well with cognitive benefits.
A researcher has developed a novel drug delivery system that transports medications to the inner ear to prevent cisplatin-induced hearing loss. The system uses hydrogels and nanoparticles to deliver drugs that block calcium damage or protect hair cells, showing promising results in early-stage studies.
A phase 1 trial found that a new oral weight loss drug, Amycretin, resulted in significant weight loss of up to 13% over three months. The drug targets both amylin and glucagon-like peptide-1 (GLP-1) biology, leading to appetite regulation and reduced hunger.
Researchers have developed a semaglutide hydrogel that could reduce diabetes shots to once a month, improving drug adherence and quality of life. The hydrogel's slow release of semaglutide over one month was found to be well-tolerated in laboratory rats with no inflammatory reactions.
Researchers developed a gene therapy that restored useful vision to most patients with Leber congenital amaurosis type I, a rare inherited blindness. The treatment showed a 10,000-fold improvement in light sensitivity and improved navigation abilities in patients who received the highest dose.
A clinical trial led by Washington University School of Medicine found that two anti-coagulant drugs did not improve outcomes for patients who received vessel-clearing interventions after a blood clot in the brain. The study aimed to test whether adding these medications could prevent further clots, but results showed no benefit.
A clinical trial led by UC San Francisco aims to develop new therapies for progressive supranuclear palsy, with a focus on reducing time to find effective treatments and increasing diverse participant enrollment. The five-year grant could lead to the first effective drugs for this incurable neurodegenerative disorder.
Researchers investigated peptide clumping behavior using molecular dynamics simulations and AI techniques. They discovered that aromatic amino acids enhance aggregation, while hydrophilic ones inhibit it, offering insights into peptide structure and function.